ArticleFrontiers in oncology2026
Glecirasib treatment in
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leptomeningeal metastasis (LM) is associated with poor outcomes in non-small cell lung cancer (NSCLC), and clinical evidence for Methods: This retrospective case series included patients treated with glecirasib at Affiliated Brain Hospital of Nanjing Medical University between January 2025 and June 2026. Intracranial progression-free survival (iPFS) and overall survival (OS) were summarized descriptively. Exploratory serial CSF circulating tumor DNA (ctDNA) analyses were performed in two selected patients. Results: Seven patients were included, with a median observed follow-up of 6.3 months (range, 2.4-9.6). The best overall LM assessment was response in five patients, stable disease in one, and progressive disease in one. Two patients developed LM progression and one patient died; median iPFS and OS were not reached. In the patient with acquired Conclusions: In this retrospective series of seven patients, glecirasib monotherapy was associated with LM disease control in six patients, suggesting possible activity in KRAS G12C-positive NSCLC with LM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.